These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20946097)

  • 1. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
    Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
    Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etravirine.
    Deeks ED; Keating GM
    Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
    Katlama C; Clotet B; Mills A; Trottier B; Molina JM; Grinsztejn B; Towner W; Haubrich R; Nijs S; Vingerhoets J; Woodfall B; Witek J
    Antivir Ther; 2010; 15(7):1045-52. PubMed ID: 21041921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
    Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
    AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
    Madruga JV; Cahn P; Grinsztejn B; Haubrich R; Lalezari J; Mills A; Pialoux G; Wilkin T; Peeters M; Vingerhoets J; de Smedt G; Leopold L; Trefiglio R; Woodfall B;
    Lancet; 2007 Jul; 370(9581):29-38. PubMed ID: 17617270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.
    Croxtall JD
    Drugs; 2012 Apr; 72(6):847-69. PubMed ID: 22512366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Etravirine in first-line therapy].
    Garcés PA; Tena EV
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():12-20. PubMed ID: 20116623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etravirine for the treatment of HIV/AIDS.
    Schrijvers R
    Expert Opin Pharmacother; 2013 Jun; 14(8):1087-96. PubMed ID: 23560740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
    Clotet B; Clumeck N; Katlama C; Nijs S; Witek J
    J Antimicrob Chemother; 2010 Nov; 65(11):2450-4. PubMed ID: 20801782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Etravirine in highly treatment-experienced patients].
    Palter DP; Corbera EF; Tiraboschi JM
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
    Tambuyzer L; Vingerhoets J; Azijn H; Daems B; Nijs S; de Béthune MP; Picchio G
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1197-205. PubMed ID: 20854144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
    ; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
    AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etravirine: new drug. Multidrug-resistant HIV: another option.
    Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US.
    Lyseng-Williamson KA
    Paediatr Drugs; 2012 Oct; 14(5):345-50. PubMed ID: 22897163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
    Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
    HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etravirine.
    Knoll BM; Vento S; Temesgen Z
    Drugs Today (Barc); 2008 Jan; 44(1):23-33. PubMed ID: 18301801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.
    Jayaweera DT; Espinoza L; Castro J
    Expert Opin Pharmacother; 2008 Dec; 9(17):3083-94. PubMed ID: 19006480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etravirine: R165335, TMC 125, TMC-125, TMC125.
    Drugs R D; 2006; 7(6):367-73. PubMed ID: 17073519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.